Research programme: Bcl-2 inhibitors - Infinity/Novartis

Drug Profile

Research programme: Bcl-2 inhibitors - Infinity/Novartis

Alternative Names: Bcl-2 inhibitors - Infinity/Novartis

Latest Information Update: 30 Apr 2012

Price : $50

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Novartis
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Cancer

Most Recent Events

  • 30 Apr 2012 Early research is ongoing in USA
  • 06 Mar 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top